Drug intelligence / Profile preview

Bufe Granules

Development stage: Unknown
Lead developer: Tianjin Pharmaceutical Da Ren Tang Group
Administration: Oral

Overview

Bufe Granules (补肺颗粒) is a Traditional Chinese Medicine (TCM) formulation developed by Tianjin Zhongxin Pharmaceutical Group No. 6 Chinese Medicine (a subsidiary of Tianjin Darentang). It is an oral granule preparation indicated for the treatment of respiratory and lung diseases. The drug is currently in Phase 2 clinical development. As a TCM product, its therapeutic approach is based on traditional principles of tonifying the lungs through a synergistic combination of herbal ingredients, rather than targeting a specific molecular pathway or receptor common in Western medicine.

Other names: 补肺颗粒Bufei Keli

Beyond the preview

Go deeper on Bufe Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bufe Granules.

Explore the full profile